Recent Advances in the Diagnosis and Management of Autoimmune Pancreatitis: Similarities and Differences in Japan and Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Two subtypes (types 1 and 2) of autoimmune pancreatitis (AIP) are currently recognized. Type 1 AIP is related to immunoglobulin G4 (lymphoplasmacytic sclerosing pancreatitis),and type 2 AIP is characterized by neutrophilic infiltration into the epithelium of the pancreatic duct (idiopathic duct-centric pancreatitis). Although type 2 AIP is sometimes observed in the United States and Europe, most cases of AIP in Japan and Korea are type 1. The international consensus diagnostic criteria for AIP were created to be applicable worldwide and to distinguish between the two types of AIP. AIP is diagnosed based on the presence of at least one of the five cardinal features (i.e., imaging, serology, other organ involvement,histology, and response to steroid therapy). Oral steroids are the standard therapy for AIP, but immunomodulatory drugs or rituximab have been successfully used for patients with relapsed AIP in the United States and Europe. Generally, the clinical manifestations and demography of AIP are similar between Japan and Korea. However, there are differences in some aspects of the disease, including the proportion of other organ involvement, the prevalence of type 2 AIP, diagnostic criteria and maintenance therapy between the two countries.
Abstract
Two subtypes (types 1 and 2) of autoimmune pancreatitis (AIP) are currently recognized. Type 1 AIP is related to immunoglobulin G4 (lymphoplasmacytic sclerosing pancreatitis),and type 2 AIP is characterized by neutrophilic infiltration into the epithelium of the pancreatic duct (idiopathic duct-centric pancreatitis). Although type 2 AIP is sometimes observed in the United States and Europe, most cases of AIP in Japan and Korea are type 1. The international consensus diagnostic criteria for AIP were created to be applicable worldwide and to distinguish between the two types of AIP. AIP is diagnosed based on the presence of at least one of the five cardinal features (i.e., imaging, serology, other organ involvement,histology, and response to steroid therapy). Oral steroids are the standard therapy for AIP, but immunomodulatory drugs or rituximab have been successfully used for patients with relapsed AIP in the United States and Europe. Generally, the clinical manifestations and demography of AIP are similar between Japan and Korea. However, there are differences in some aspects of the disease, including the proportion of other organ involvement, the prevalence of type 2 AIP, diagnostic criteria and maintenance therapy between the two countries.
참고문헌 (35)
- Kamisawa T, "A new clinicopathological entity of IgG4-related autoimmune disease", J Gastroenterol, 38, pp.982~984 (2003)
- Stone JH, "Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations", Arthritis Rheum, 64, pp.3061~3067 (2012)
- Yoshida K, "Chronic pancreatitis caused by an autoimmune abnormality. Proposal of the concept of autoimmune pancreatitis", Dig Dis Sci, 40, pp.1561~1568 (1995)
- Members of the Criteria Committee for Autoimmune Pancreatitis of the Japan Pancreas Society, "Diagnostic criteria for autoimmune pancreatitis by the Japan Pancreas Society", J Jpn Pancreas Soc, 17, pp.585~587 (2002)
- Pearson RK, "Controversies in clinical pancreatology: autoimmune pancreatitis: does it exist?", Pancreas, 27, pp.1~13 (2003)
- Okazaki K, "Clinical diagnostic criteria of autoimmune pancreatitis: revised proposal", J Gastroenterol, 41, pp.626~631 (2006)
- Kim KP, "Diagnostic criteria for autoimmune chronic pancreatitis revisited", World J Gastroenterol, 12, pp.2487~2496 (2006)
- Chari ST, "Autoimmune pancreatitis: diagnosis using histology, imaging, serology, other organ involvement and response to steroids", Pancreas, 31, pp.435~436 (2005)
- "Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis", Journal Of Gastroenterology, 43, pp.403~408 (2008)
- Chari ST, "A diagnostic strategy to distinguish autoimmune pancreatitis from pancreatic cancer", Clin Gastroenterol Hepatol, 7, pp.1097~1103 (2009)
- Shimosegawa T, "International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology", Pancreas, 40, pp.352~358 (2011)
- Kawaguchi K, "Lymphoplasmacytic sclerosing pancreatitis with cholangitis: a variant of primary sclerosing cholangitis extensively involving pancreas", Hum Pathol, 22, pp.387~395 (1991)
- Notohara K, "Idiopathic chronic pancreatitis with periductal lymphoplasmacytic infiltration: clinicopathologic features of 35 cases", Am J Surg Pathol, 27, pp.1119~1127 (2003)
- Zamboni G, "Histopathological features of diagnostic and clinical relevance in autoimmune pancreatitis: a study on 53 resection specimens and 9 biopsy specimens", Virchows Arch, 445, pp.552~563 (2004)
- Park DH, "Recent advances in autoimmune pancreatitis", Gut, 58, pp.1680~1689 (2009)
- Sah RP, "Differences in clinical profile and relapse rate of type 1 versus type 2 autoimmune pancreatitis", Gastroenterology, 139, pp.140~148 (2010)
- Kamisawa T, "Autoimmune pancreatitis and IgG4-related sclerosing disease", Nat Rev Gastroenterol Hepatol, 7, pp.401~409 (2010)
- Kamisawa T, "Two clinicopathologic subtypes of autoimmune pancreatitis: LPSP and IDCP", Gastroenterology, 139, pp.22~25 (2010)
- Kamisawa T, "Clinical profile of autoimmune pancreatitis and its histological subtypes: an international multicenter survey", Pancreas, 40, pp.809~814 (2011)
- Hart PA, "Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis", Gut (2012)[DOI]
- Kamisawa T, "Standard steroid treatment for autoimmune pancreatitis", Gut, 58, pp.1504~1507 (2009)
- Kamisawa T, "Research Committee for Intractable Pancreatic Disease and Japan Pancreas Society. Japanese consensus guidelines for management of autoimmune pancreatitis: III. Treatment and prognosis of AIP", J Gastroenterol, 45, pp.471~477 (2010)
- Ghazale A, "Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy", Gastroenterology, 134, pp.706~715 (2008)
- Hart PA, "Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience", Gut (2012)[DOI]
- Sandanayake NS, "Presentation and management of post-treatment relapse in autoimmune pancreatitis", immunoglobulin G4-associated cholangitis, 2009, pp.7, 1089~1096
- Takuma K, "Short-term and long-term outcomes of autoimmune pancreatitis", Eur J Gastroenterol Hepatol, 23, pp.146~152 (2011)
- Maruyama M, "Risk factors for pancreatic stone formation in autoimmune pancreatitis over a long-term course", J Gastroenterol, 47, pp.553~560 (2012)
- Kim JY, "A case of autoimmune chronic pancreatitis improved with oral steroid therapy", Korean J Gastroenterol, 39, pp.304~308 (2002)
- "Review of 67 patients with autoimmune pancreatitis in korea: A multicenter nationwide study", Pancreas, 37(4), pp.377~385 (2008), LIPPINCOTT WILLIAMS & WILKINS
- 박수정, "자가면역췌장염 55예의 임상 특징, 재발 양상 및 치료 성적", 대한소화기학회지, 52(4), pp.230~246 (2008), 대한소화기학회
- Kamisawa T, "Clinical characteristics of 327 Asian patients with autoimmune pancreatitis based on Asian diagnostic criteria", Pancreas, 40, pp.200~205 (2011)
- Song TJ, "Comparison of clinical findings between histologically confirmed type 1 and type 2 autoimmune pancreatitis", J Gastroenterol Hepatol, 27, pp.700~708 (2012)
- Iwashita T, "Use of samples from endoscopic ultrasound-guided 19-gauge fine-needle aspiration in diagnosis of autoimmune pancreatitis", Clin Gastroenterol Hepatol, 10, pp.316~322 (2012)
- Bang JY, "Randomized trial comparing the 22-gauge aspiration and 22-gauge biopsy needles for EUS-guided sampling of solid pancreatic mass lesions", Gastrointest Endosc, 76, pp.321~327 (2012)
- "Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study", GUT, 57, pp.1704~1712 (2008), B M J PUBLISHING GROUP